title: Prevention versus intervention of type 1 diabetes.
abstract: Type 1 diabetes (T1D) is a cell-mediated autoimmune disease. New cases of T1D are on the increase and exogenous insulin therapy is the only intervention regularly initiated for T1D patients. Though tremendous strides have been made in prediction of T1D, prevention and intervention strategies have not experienced the same success. In this review, we will discuss some possible reasons why new intervention therapies for T1D have not been implemented into the mainstream treatment regimen for T1D patients. We will also discuss potential caveats for why prevention and intervention trials in T1D may not have experienced the same success as prediction trials.
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA 98108, USA; Department of Medicine, VA Puget Sound Health Care System, Seattle, WA 98108, USA. Electronic address: bbrooks@u.washington.edu.
authors.forename: Barbara
authors.initials: B
authors.lastname: Brooks-Worrell
authors.forename: Jerry P
authors.initials: JP
authors.lastname: Palmer
mesh_terms: D000069594:Abatacept; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D015551:Autoimmunity; D017252:CD3 Complex / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control*; D000068800:Etanercept; D005968:Glutamate Decarboxylase / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D018796:Immunoconjugates / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D017252:CD3 Complex; D007004:Hypoglycemic Agents; D018796:Immunoconjugates; D007074:Immunoglobulin G; D007328:Insulin; D018124:Receptors, Tumor Necrosis Factor; D000069594:Abatacept; D005968:Glutamate Decarboxylase; D000068800:Etanercept; C502540:teplizumab
keywords: Intervention; Islet autoimmunity; Prediction; Prevention; Type 1 diabetes; Type 2 diabetes